LIVE EVENT: The U.S. healthcare law rollout: Where do we stand?
TEL AVIV - Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities (NTEs) could generate revenue of $1 billion to $1.5 billion by 2018.
- A closely watched leukemia drug developed by Johnson & Johnson and Pharmacyclics Inc maintained its effectiveness in keeping the disease at bay for most patients, according to long-term follow-up data from a midstage study being presented at a major medical meeting.
- An experimental AbbVie Inc drug for leukemia controlled or eliminated signs of the disease in more than 80 percent of patients who had failed to benefit from previous treatments, an unprecedented finding that could spur use of the medicine for other cancers, researchers said.
ORLANDO, Florida - A Florida researcher is preparing to test massive dust storms in the upper atmosphere that roll in from Africa to see whether pathogens raining down on the state could be responsible for plant, animal or human disease.
FAYETTEVILLE, North Carolina - Water pollution at the Camp Lejeune military base in North Carolina has been linked to increased risk of birth defects and childhood cancers, according to the U.S. Centers for Disease Control and Prevention.
MEXICO CITY - Six men suspected of stealing a dangerous radioactive cargo from a truck outside Mexico City earlier this week have been treated in a hospital for signs of radiation exposure and remain under police guard, officials said on Friday.
- U.S. health regulators on Friday approved Auxilium Pharmaceuticals Inc's Xiaflex injections to treat a condition that causes a painful curvature of the penis called Peyronie's disease.
- U.S. regulators on Friday approved Gilead Sciences Inc's Sovaldi as a potentially easier cure for chronic infection with the liver-destroying hepatitis C virus.
BASEL - Fifteen years ago Ian Parkhill was diagnosed with a rare muscle-wasting disease that gradually robbed him of the strength in his thighs.
- GlaxoSmithKline and Theravance Inc said on Friday that their combination therapy met the main goal of improving lung function in asthma patients in a late-stage trial.
On Wednesday, December 4 at 10:30 a.m. watch live as experts assess where the U.S. stands in the healthcare law rollout and the resulting health policy implications. Presented by the forum at Harvard School of Public Health in collaboration with Reuters. Live Coverage